Recent Investment Analysts’ Ratings Updates for Spark Therapeutics (ONCE)

Spark Therapeutics (NASDAQ: ONCE) has recently received a number of price target changes and ratings updates:

  • 8/8/2018 – Spark Therapeutics had its price target lowered by analysts at Royal Bank of Canada to $64.00. They now have a “sector perform” rating on the stock.
  • 8/8/2018 – Spark Therapeutics had its price target lowered by analysts at Barclays PLC from $85.00 to $77.00. They now have an “overweight” rating on the stock.
  • 8/8/2018 – Spark Therapeutics had its price target lowered by analysts at UBS Group AG from $80.00 to $53.00. They now have a “neutral” rating on the stock.
  • 8/8/2018 – Spark Therapeutics had its price target raised by analysts at Chardan Capital from $60.00 to $85.00. They now have a “neutral” rating on the stock.
  • 8/8/2018 – Spark Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/8/2018 – Spark Therapeutics had its price target lowered by analysts at SunTrust Banks, Inc. to $61.00. They now have a “buy” rating on the stock.
  • 8/8/2018 – Spark Therapeutics was given a new $82.00 price target on by analysts at Raymond James. They now have a “buy” rating on the stock.
  • 8/8/2018 – Spark Therapeutics had its price target lowered by analysts at Stifel Nicolaus from $76.00 to $68.00. They now have a “buy” rating on the stock.
  • 8/8/2018 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $77.00 price target on the stock. They wrote, “We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN, non-rated). We reduce our PT from $91 to $77 after removing the M&A premium of our valuation per revised valuation methodology and we maintain our revenue forecasts.””
  • 8/7/2018 – Spark Therapeutics had its “underperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $98.00 price target on the stock.
  • 8/7/2018 – Spark Therapeutics was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $60.00 price target on the stock.
  • 8/7/2018 – Spark Therapeutics had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $55.00 price target on the stock, down previously from $74.00.
  • 8/7/2018 – Spark Therapeutics was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating.
  • 8/7/2018 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $103.00 price target on the stock. They wrote, “: We reiterate our Overweight rating and 12-month PT of $103 on 2Q18 financial results and program updates. During the call, Spark announced additional updates from the Phase 1/2 trial of SPK-8011 in hemophilia A. While the occurrence of two immune responses leading to inadequate FVIII activity level add challenges for the program, we believe the company is well equipped to address them as the program moves to late-stage development.””
  • 7/24/2018 – Spark Therapeutics was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 7/19/2018 – Spark Therapeutics was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $100.00 price target on the stock.
  • 7/16/2018 – Spark Therapeutics was given a new $103.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/9/2018 – Spark Therapeutics had its price target raised by analysts at Credit Suisse Group AG from $75.00 to $98.00. They now have an “outperform” rating on the stock.
  • 6/28/2018 – Spark Therapeutics is now covered by analysts at B. Riley. They set a “neutral” rating and a $74.00 price target on the stock.
  • 6/26/2018 – Spark Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 6/25/2018 – Spark Therapeutics had its price target raised by analysts at BMO Capital Markets from $78.00 to $98.00. They now have an “outperform” rating on the stock.
  • 6/18/2018 – Spark Therapeutics was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.

Shares of ONCE stock opened at $62.01 on Friday. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -8.13 and a beta of 2.39. Spark Therapeutics Inc has a 52 week low of $41.06 and a 52 week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.34). The company had revenue of $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%. equities analysts forecast that Spark Therapeutics Inc will post -2.15 EPS for the current year.

Hedge funds have recently made changes to their positions in the business. Swiss National Bank raised its position in Spark Therapeutics by 6.4% in the first quarter. Swiss National Bank now owns 54,700 shares of the biotechnology company’s stock worth $3,642,000 after acquiring an additional 3,300 shares during the period. Xact Kapitalforvaltning AB bought a new stake in Spark Therapeutics in the fourth quarter worth about $208,000. Pinnacle Associates Ltd. purchased a new position in shares of Spark Therapeutics in the first quarter worth about $15,611,000. Fox Run Management L.L.C. purchased a new position in shares of Spark Therapeutics in the second quarter worth about $533,000. Finally, NJ State Employees Deferred Compensation Plan purchased a new position in shares of Spark Therapeutics in the first quarter worth about $266,000.

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Story: Google Finance

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply